comparemela.com

Latest Breaking News On - Eris lifesciences - Page 14 : comparemela.com

Nifty Pharma hits all-time high; 10 stocks including Lupin, Cipla, Glenmark Pharma, Divi s Labs touch one-year peaks

In today s trade, Lupin s shares soared nearly 7%, hitting a new all-time high of ₹1,404 apiece after Japanese brokerage firm Nomura raised the target price on the stock to ₹1,593 apiece from the previous ₹1,290, maintaining its buy recommendation.

ChrysCapital eyes stake in Delhi s Centre For Sight eye hospital

ChrysCapital s proposed investment will give an exit to Mahindra Partners, the PE arm of Mahindra & Mahindra, which owns about 32% stake in the chain. At present, Centre For Sight founder Dr Mahipal S Sachdev is the majority stakeholder with about 55% stake in the chain. Another 10% stake has been given under employee stock ownership plan.

From Mumbai to Jaipur: Cities that have produced maximum self-made entrepreneurs

In the vibrant tapestry of India s entrepreneurial landscape, certain cities stand out as incubators for a remarkable phenomenon – the rise of self-made entrepreneurs.

nifty target: Nifty may cross 22,500 in 12 months, says Prabhudas Lilladher; picks Hindalco, 3 more stocks as conviction buys

Nifty is trading at a 17.2% discount to the 10-year average which provides comfort to Prabhudas who believes that the headline index is not trading in a bubble zone. The 50-stock index has remained flattish in the past 6 weeks and given just 1.6% return in the quarter gone by, riding on inflows of the domestic institutional investors (DIIs) even as the foreign institutional investors (FIIs) preferred selling the domestic equities, the note said.

Prabhudas Lilladher sees Nifty at 22,584 in 12 months; lists top stock picks

Indian market has taken all headwinds in its stride and the action has been very stock-specific as Mid/small caps continue to outperform large caps, Prabhudas Lilladher stated. It lists its top large, mid and smallcap picks for model portfolio.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.